AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamelin, M.-E.
Right arrow Articles by Boivin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamelin, M.-E.
Right arrow Articles by Boivin, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 774-777, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.774-777.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Effect of Ribavirin and Glucocorticoid Treatment in a Mouse Model of Human Metapneumovirus Infection

Marie-Ève Hamelin,1,2* Gregory A. Prince,3 and Guy Boivin1,2*

Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec, Sainte-Foy, Québec, Canada;,1 Laval University, Québec City, Québec, Canada,2 Virion Systems, Inc., Rockville, Maryland3

Received 30 August 2005/ Returned for modification 9 November 2005/ Accepted 23 November 2005

Human metapneumovirus (hMPV)-infected BALB/c mice were treated with ribavirin (40 mg/kg of body weight twice a day intraperitoneally), corticosterone (0.2 mg/ml in water), or both modalities. Ribavirin significantly decreased both hMPV replication in lungs (by 5 log10) and global pulmonary inflammation on day 5 postinfection, whereas glucocorticoids reduced only alveolar and interstitial inflammation, compared to controls.

* Corresponding author. Mailing address: CHUQ-CHUL, room RC-709, 2705 blvd. Laurier, Sainte-Foy, Québec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail for G. Boivin: Guy.Boivin{at}crchul.ulaval.ca. E-mail for M.-E. Hamelin: Marie-eve.Hamelin{at}crchul.ulaval.ca.

Antimicrobial Agents and Chemotherapy, February 2006, p. 774-777, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.774-777.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.